

FACT SHEET

Fourth Quarter 2009

Issued Feb. 16, 2010

website: www.tevapharm.com



TEVA PHARMACEUTICAL INDUSTRIES LTD.




CONTACT INFORMATION: **Elana Holzman** Tel +972-3-926-7554, E-mail: elana.holzman@teva.co.il **Kevin Mannix** Tel (215) 591-8912, E-mail: kevin.mannix@tevausa.com

COMPANY OVERVIEW

Teva Pharmaceutical Industries Ltd., is among the top 20 pharmaceutical companies in the world and the leader in generic pharmaceuticals, specializing in development, production and marketing of a wide range of generic, innovative and branded pharmaceuticals, biogenerics and active pharmaceutical ingredients. Teva currently operates in over 60 countries with some 35,000 employees worldwide. Its innovative R&D efforts focus on therapies for the central nervous system (with emphasis on multiple sclerosis), autoimmune

diseases and oncology. Teva differentiates itself by balancing its portfolio with generic, innovative and branded products, vertically integrating its pharmaceutical and API activities, combining local customer responsiveness with a "global edge", and by its global footprint. Teva's success lies in the leadership of its management, the skills and devotion of its people, the quality of its offerings and its focus on customers and patients.

NET SALES (U.S. \$ in Millions)




MARKET DATA (As of Feb. 12, 2010)

Stock Symbol	TEVA
Closing Price	\$58.86
52 Week Range	\$42.67 - \$59.62
Market Capitalization	\$51.86 billion
#9 in NASDAQ-100	


NASDAQ-100




NET INCOME^(1,2) (U.S. \$ in Millions)




STOCK CHART (As of Feb. 12, 2010)



EARNING PER SHARE^(1,2) (U.S. \$ in Millions)



R&D EXPENSES (NET) (U.S. \$ in Millions)



(1) Reflects non-GAAP results. (2) Reflects retroactive adjustment following the adoption of APB14-1.



TEVA PHARMACEUTICAL INDUSTRIES LTD.



RECENT EVENTS

February 2, 2010 - The FDA has accepted for filing Teva's Biologics License Application (BLA) for XM02, a G-CSF for the reduction in the duration of severe neutropenia, submitted on November 30, 2009. XM02 was developed as a similar biological medicinal product to Neupogen®. Teva's G-CSF received marketing authorization in the EU in September 2008 and is marketed under the brand name TevaGrastim®.

January 22, 2010 - The U.S. Court of Appeals for the Federal Circuit has affirmed a November 10, 2009, District Court decision that Teva's generic version of Takeda's Prevacid® (lansoprazole) SoluTab does not infringe U.S. Patent No 5,464,632. Annual sales of the brand product in the U.S. were approximately \$513 million.

January 7, 2010 - During its investor meeting, Teva presented an updated strategy and announced its long-term goals of reaching revenues of \$31 billion and non-GAAP net income of \$6.8 billion, or 22% of revenues, by 2015. Key growth opportunities include – generics, the Company's core business, driven by the growing worldwide demand for generic pharmaceuticals; an expanded innovative and branded business; and in the longer term, biosimilars, an evolving market in which Teva is committed to becoming a leading player.

December 24, 2009 - Teva-KOWA Pharma Co., Ltd., Teva's joint venture in Japan with KOWA Company, Ltd., acquired approximately 69% of the outstanding shares of Taisho Pharmaceutical Industries Ltd. Taisho is a privately-held company with revenues of over \$130 million; it manufactures and markets a portfolio of over 200 generic products. The acquisition will further Teva-KOWA Pharma in its strategic objective to become the provider of choice of high-quality affordable generic medicine in the Japanese market.


December 21, 2009 - Teva and OncoGenex Pharmaceuticals, Inc. have entered into a global license and collaboration agreement to develop and commercialize OGX-011 shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance and enhance the effectiveness of chemotherapy.

December 14, 2009 - The FDA approved newly revised prescribing information for Azilect® reducing medication and food restrictions. The new label reflects reduced concerns regarding the use of Azilect® together with certain medications, including over-the-counter cough/cold medications. Also, patients taking Azilect® no longer need to follow a general dietary restriction of ordinary levels of tyramine, an amino acid found in certain foods and beverages.

SALES BY REGION

Q4/09: \$3.8 billion

North America	61%
Europe ⁽¹⁾	24%
Latin America ⁽²⁾	6%
Israel	3%
CEE	4%
ROW	2%




(1) Includes EU member states, Switzerland & Norway
(2) Includes Mexico


U.S. GENERIC PIPELINE (As of Feb 5, 2010)

216 ANDAs -
Over \$113 billion in total branded sales
140 Paragraph IV Filings
89 First-To-File
Over \$55 Billion In Total Branded Sales

COPAXONE® - GLOBAL IN-MARKET SALES (U.S. \$ in Millions)



PROPRIETARY BRANDED PHARMACEUTICALS - PIPELINE



SELECTED GENERIC APPROVALS U.S. NOVEMBER 2009 - JANUARY 2010

Product	Approval/Launch Date	Branded Product		Indication
		Name	Market size (U.S. \$ in Millions)	
Fentanyl Citrate ⁽¹⁾	30/10/09	Actiq®	1,076	Treatment of breakthrough cancer pain.
Rosiglitazone & Glimepiride ⁽³⁾	2/11/09	Avandaryl®	228	Treatment of type 2 diabetes.
Lansoprazole DR ⁽¹⁾	10/11/09	Prevacid®	2,576	Proton pump inhibitor, indicated for various GI disorders such as GERD.
Atomoxetine HCl ⁽³⁾	25/11/09	Strattera®	527	Treatment of ADHD.
Letrozole ⁽³⁾	20/01/10	Femara®	585	Breast cancer therapy.
Lamivudine/Zidovudine ⁽³⁾	24/12/09	Combivir®	367	Treatment of HIV.

1 Launched 2 Exclusivity (180 days) 3 Tentative approval